Amylyx Pharmaceuticals, Inc. AMLX Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amylyx Pharmaceuticals, Inc.'s operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amylyx Pharmaceuticals, Inc.'s operating lease liabilities (current)?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported operating lease liabilities (current) of $1.16M in Q1 2026.
- How has Amylyx Pharmaceuticals, Inc.'s operating lease liabilities (current) changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s operating lease liabilities (current) increased by 9.5% year-over-year, from $1.06M to $1.16M.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s operating lease liabilities (current)?
- Over 3 years (2022 to 2025), Amylyx Pharmaceuticals, Inc.'s operating lease liabilities (current) has grown at a -14.9% compound annual growth rate (CAGR), from $2.04M to $1.26M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.